OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice
Vadim V. Klimontov, Anton I. Korbut, Iuliia Taskaeva, et al.
World Journal of Diabetes (2020) Vol. 11, Iss. 12, pp. 596-610
Open Access | Times Cited: 22
Vadim V. Klimontov, Anton I. Korbut, Iuliia Taskaeva, et al.
World Journal of Diabetes (2020) Vol. 11, Iss. 12, pp. 596-610
Open Access | Times Cited: 22
Showing 22 citing articles:
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
Xinyu Zhao, Shuangshuang Li, Ying-xin He, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 10, pp. 1328-1340
Closed Access | Times Cited: 51
Xinyu Zhao, Shuangshuang Li, Ying-xin He, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 10, pp. 1328-1340
Closed Access | Times Cited: 51
Green tea peptides ameliorate diabetic nephropathy by inhibiting the TGF-β/Smad signaling pathway in mice
Xuhui Chen, Lingli Sun, Dongli Li, et al.
Food & Function (2022) Vol. 13, Iss. 6, pp. 3258-3270
Closed Access | Times Cited: 27
Xuhui Chen, Lingli Sun, Dongli Li, et al.
Food & Function (2022) Vol. 13, Iss. 6, pp. 3258-3270
Closed Access | Times Cited: 27
Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway
Jingshu Sun, Xinyu Zhang, Simeng Wang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Jingshu Sun, Xinyu Zhang, Simeng Wang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 5
Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease
Raysa S. Farias, Rodrigo P. Silva‐Aguiar, Douglas E. Teixeira, et al.
European Journal of Pharmacology (2023) Vol. 942, pp. 175521-175521
Closed Access | Times Cited: 12
Raysa S. Farias, Rodrigo P. Silva‐Aguiar, Douglas E. Teixeira, et al.
European Journal of Pharmacology (2023) Vol. 942, pp. 175521-175521
Closed Access | Times Cited: 12
SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway
Xiaochun Zeng, Yuan Tian, Xianming Liang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Xiaochun Zeng, Yuan Tian, Xianming Liang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Modified Citrus Pectin (MCP) Confers a Renoprotective Effect on Early‐Stage Nephropathy in Type‐2 Diabetic Mice
Hager M. Mahmoud, Abdel‐Razik H. Abdel‐Razik, Mahmoud A. Elrehany, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 7
Closed Access | Times Cited: 3
Hager M. Mahmoud, Abdel‐Razik H. Abdel‐Razik, Mahmoud A. Elrehany, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 7
Closed Access | Times Cited: 3
SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial
Yuan Tian, Xiaohong Chen, Xianming Liang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Yuan Tian, Xiaohong Chen, Xianming Liang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 14
Galantamine improves glycemic control and diabetic nephropathy in Leprdb/db mice
Qinghe Meng, Julia Ma, Liye Suo, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Qinghe Meng, Julia Ma, Liye Suo, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes
Xue Li, Qiong Li, Xinying Jiang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Xue Li, Qiong Li, Xinying Jiang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes
Yun Wen, Xiaofang Zhang, Han Liu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Yun Wen, Xiaofang Zhang, Han Liu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy
Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108503-108503
Closed Access | Times Cited: 6
Aqsa Ashfaq, Myriam Meineck, Andrea Pautz, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108503-108503
Closed Access | Times Cited: 6
Is type 2 diabetes mellitus another intercellular junction-related disorder?
Carla Beatriz Collares‐Buzato, Carolina Prado de França Carvalho
Experimental Biology and Medicine (2022) Vol. 247, Iss. 9, pp. 743-755
Open Access | Times Cited: 9
Carla Beatriz Collares‐Buzato, Carolina Prado de França Carvalho
Experimental Biology and Medicine (2022) Vol. 247, Iss. 9, pp. 743-755
Open Access | Times Cited: 9
High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease
Meina Zou, Yanrong Chen, Zongji Zheng, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 9
Meina Zou, Yanrong Chen, Zongji Zheng, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 9
The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats
Yasemin Korkmaz, Burak Dik
Fundamental and Clinical Pharmacology (2023) Vol. 38, Iss. 3, pp. 511-522
Closed Access | Times Cited: 3
Yasemin Korkmaz, Burak Dik
Fundamental and Clinical Pharmacology (2023) Vol. 38, Iss. 3, pp. 511-522
Closed Access | Times Cited: 3
SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
Panagiotis Theofilis, Rigas Kalaitzidis
Current Medicinal Chemistry (2022) Vol. 30, Iss. 23, pp. 2595-2603
Closed Access | Times Cited: 4
Panagiotis Theofilis, Rigas Kalaitzidis
Current Medicinal Chemistry (2022) Vol. 30, Iss. 23, pp. 2595-2603
Closed Access | Times Cited: 4
Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease
Saurabh Nayak, Vinay Rathore, Joyita Bharati, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 12, pp. 1513-1526
Closed Access | Times Cited: 4
Saurabh Nayak, Vinay Rathore, Joyita Bharati, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 12, pp. 1513-1526
Closed Access | Times Cited: 4
Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial
Mohammad Amin Mohammad zadeh Gharabaghi, Mohammad Reza Rezvanfar, Nasser Saeedi, et al.
Clinical Diabetes and Endocrinology (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Mohammad Amin Mohammad zadeh Gharabaghi, Mohammad Reza Rezvanfar, Nasser Saeedi, et al.
Clinical Diabetes and Endocrinology (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Empagliflozin Exacerbated Lipid Metabolism Disorders in Diabetic Mice
Jianping Li, Baotong Xing, Meiling Xu, et al.
(2024)
Closed Access
Jianping Li, Baotong Xing, Meiling Xu, et al.
(2024)
Closed Access
Unveiling the podocyte-protective effect of sodium-glucose cotransporter-2 inhibitors
Buchun Jiang, Zhiwen Cheng, Dongjie Wang, et al.
Kidney Research and Clinical Practice (2024) Vol. 44, Iss. 1, pp. 69-78
Open Access
Buchun Jiang, Zhiwen Cheng, Dongjie Wang, et al.
Kidney Research and Clinical Practice (2024) Vol. 44, Iss. 1, pp. 69-78
Open Access
Dapagliflozin Improves Podocytes Injury in Diabetic Nephropathy via Regulating Cholesterol Balance Through KLF5 Targeting the ABCA1 Signalling Pathway
Qinglian Wang, Xinyu Zhang, Jingshu Sun, et al.
Research Square (Research Square) (2023)
Open Access
Qinglian Wang, Xinyu Zhang, Jingshu Sun, et al.
Research Square (Research Square) (2023)
Open Access
SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 excretion in type 2 diabetes patients with albuminuria
Yuan Tian, Xiaohong Chen, Xianming Liang, et al.
Research Square (Research Square) (2022)
Open Access
Yuan Tian, Xiaohong Chen, Xianming Liang, et al.
Research Square (Research Square) (2022)
Open Access
SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: A Randomized Clinical Trial
Yuan Tian, Xiaohong Chen, Xianming Liang, et al.
Research Square (Research Square) (2022)
Open Access
Yuan Tian, Xiaohong Chen, Xianming Liang, et al.
Research Square (Research Square) (2022)
Open Access
